Dr. Gallant is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
AXCES Research/Health
531 Harkle Road, Suite B
Santa Fe, NM 87505
Summary
- I am board certified in internal medicine and infectious diseases, with expertise in the treatment and prevention of HIV infection.
Education & Training
Johns Hopkins School of Hygiene and Public HealthMPH, Internaional Health, John C. Hume Masters in Public Health Award, Delta Omega Public Health Honor Society, 1989 - 1990
Yale-New Haven Medical CenterResidency, Internal Medicine, 1985 - 1988
University of California San Francisco School of MedicineClass of 1985
Certifications & Licensure
CA State Medical License 2019 - 2026
NM State Medical License 2024 - 2026
MD State Medical License 1989 - 2014- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- HIV Clinical Educator Award HIV Medicine Association and Infectious Disease Society of America
- Super Doctor SuperDoctors.com
Publications & Presentations
PubMed
- 2428 citationsIdentification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral TherapyDiana Finzi, Monika Hermankova, Theodore C. Pierson, Lucy M. Carruth, Christopher B. Buck
Science. 1997-11-14 - 1668 citationsLatent infection of CD4 + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapyDiana Finzi, Joel N. Blankson, Janet M. Siliciano, Joseph B. Margolick, Karen Chadwick
Nature Medicine. 1999-05-01 - 5236 citationsPrevention of HIV-1 Infection with Early Antiretroviral TherapyMyron S. Cohen, Ying Q. Chen, Marybeth McCauley, Theresa Gamble, Mina C. Hosseinipour
The New England Journal of Medicine. 2011-08-10
Lectures
- 23rd Annual Clinical Care of the Patient with HIV InfectionThe Johns Hopkins University School of Medicine, Baltimore, Maryland - 3/18/2013
Other
- Primer on interpretation of HIV drug resistance testingGallant JE, Cohen CJ
http://www.uptodate.com/contents/primer-on-interpretation-of-hiv-drug-resistance-testing
UpToDate, Wolters Kluwer Health - 2012-09-20
Press Mentions
Biktarvy Could Be Long-Term Option for Older Adults With HIVOctober 6th, 2022
Bareback: Re-Opening the Dialogue on Safer Sex in the Age of U=UMarch 5th, 2018
Fixed-Dose HIV Combo Containing Bictegravir Found to Be Safe, EffectiveJuly 24th, 2017- Join now to see all
Grant Support
- ACTG A5202National Center For Research Resources2006–2007
- ACTG A5142National Center For Research Resources2004–2007
- AIDS Related Nonhodgkin'S Lymphoma/Kaposi'S Sarcoma And Other MalignanciesNational Center For Research Resources1998–2002
- Phase II Safety, Plasma Pharmacokinetics &AntiretroviralNational Center For Research Resources1999
Professional Memberships
- Fellow
- Fellow
Other Languages
- Spanish
Industry Relationships
- Executive Director, Global Medical FfIrs, Gilead Sciences2017 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
